Reprinted from Pharmacy Practice News October 2024 Supported by inflaRx Gohibic@trade; (vilobelimab): A Treatment Option For Critically Ill COVID-19 Patients Introduction Although the COVID-19 pandemic has abated, deaths continue to outpace other respiratory viral infections.1 Health care providers face ongoing challenges of SARS-CoV-2 infection where disease severity ranges from asymptomatic or mild symptoms to severe lung inflam.mation.2,3 Some patients infected with SARS-CoV-2 develop
SEPTEMBER 23, 2024